Transcatheter Aortic Valve Implantation: Our Experience and Review of the Literature

Creative Commons License

Burgazli K. M., Chasan R., Kavukcu E., Neuhof C., Bilgin M., Soydan N., ...Daha Fazla

BALKAN MEDICAL JOURNAL, cilt.29, sa.2, ss.118-123, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 29 Sayı: 2
  • Basım Tarihi: 2012
  • Doi Numarası: 10.5152/balkanmedj.2012.004
  • Dergi Adı: BALKAN MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.118-123
  • Anahtar Kelimeler: TAVI, TAVI transfemoral, TAVI transapical, conventional aortic valve implantation, catheter-based aortic valve implantation, HIGH-RISK PATIENTS, PROSTHESIS, REPLACEMENT, RETROGRADE, OUTCOMES, STENOSIS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Transcatheter Aortic Valve Implantation [TAVI] is widespread worldwide as an alternative therapy procedure to the patients suffering from severe aortic valve stenosis. However, we shouldn't forget that the conventional surgical aortic valve replacement is still the gold standard therapy for severe aortic valve stenosis. For the patients who cannot be treated conventionally because of high risk comorbid diseases and older age, TAVI is an effective alternative therapy method. The indications should be limited, concerning the high mortality rate, 10% within 30 days of intervention. Long term efficacy data are still inadequate. Although the indications are restricted to older patients with a STS score >10 or log-Euro Score >20, age is not a definite indication for this treatment. The patients should be assessed by a heart team including a non-interventional cardiologist, interventional cardiologist, cardiac anesthesiologist and cardiac surgeon according to their general status, frailty and STS-Euro score. In other words, assessment and treatment of the patient by a heart team is the main factor besides the limited power of the scoring systems. The treatment should be applied to the patients with an aortic annulus diameter between 18-27 mm and a life expectancy of at least over 1 year. The currently ongoing investigations are focused on parameters like safety, efficiency and long term reliability of TAVI. The scientific and technical developments lead to new definitions and parameters regarding the treatment indications of severe aortic valve stenosis. In this review, we present the actual data about TAVI and also our own experiences.

Transcatheter Aortic Valve Implantation: Our Experience and Review of the Literature

By:Burgazli, KM (Burgazli, Kamil Mehmet)[ 1 ] ; Chasan, R (Chasan, Ritvan)[ 1 ] ; Kavukcu, E (Kavukcu, Ethem)[ 2 ] ; Neuhof, C (Neuhof, Christiane)[ 1 ] ; Bilgin, M (Bilgin, Mehmet)[ 1 ] ; Soydan, N (Soydan, Nedim)[ 1 ] ; Erdogan, A (Erdogan, Ali)[ 1 ]

 

BALKAN MEDICAL JOURNAL

 

Volume:29

Issue:2

Pages:118-123

DOI:10.5152/balkanmedj.2012.004

Published:2012

View Journal Information

BALKAN MEDICAL JOURNAL

JCR® Category Quartile in Category
MEDICINE, GENERAL & INTERNAL Q4

Data from the 2013 edition of Journal Citation Reports®

Publisher AVES YAYINCILIK, IBRAHIM KARA, KIZILELMA CAD 5-3, FINDIKZADE, ISTANBUL 34096, TURKEY

ISSN: 2146-3123

Research Domain General & Internal Medicine

Abstract

Transcatheter Aortic Valve Implantation [TAVI] is widespread worldwide as an alternative therapy procedure to the patients suffering from severe aortic valve stenosis. However, we shouldn't forget that the conventional surgical aortic valve replacement is still the gold standard therapy for severe aortic valve stenosis. For the patients who cannot be treated conventionally because of high risk comorbid diseases and older age, TAVI is an effective alternative therapy method. The indications should be limited, concerning the high mortality rate, 10% within 30 days of intervention. Long term efficacy data are still inadequate. Although the indications are restricted to older patients with a STS score >10 or log-Euro Score >20, age is not a definite indication for this treatment. The patients should be assessed by a heart team including a non-interventional cardiologist, interventional cardiologist, cardiac anesthesiologist and cardiac surgeon according to their general status, frailty and STS-Euro score. In other words, assessment and treatment of the patient by a heart team is the main factor besides the limited power of the scoring systems. The treatment should be applied to the patients with an aortic annulus diameter between 18-27 mm and a life expectancy of at least over 1 year. The currently ongoing investigations are focused on parameters like safety, efficiency and long term reliability of TAVI. The scientific and technical developments lead to new definitions and parameters regarding the treatment indications of severe aortic valve stenosis. In this review, we present the actual data about TAVI and also our own experiences.

Author Information

Reprint Address: Burgazli, KM (reprint author)

  Wichlinghauser Str 110-112, D-42277 Wuppertal, Germany.

 

Addresses:

[ 1 ] Univ Giessen, Dept Internal Med, Div Cardiol, Giessen, Germany
Organization-Enhanced Name(s)
Justus Liebig University Giessen
  [ 2 ] Med Ctr Wuppertal, Dept Internal Med, Wuppertal, Germany

 

E-mail Addresses:mehmetburgazli@hotmail.de

Publisher

AVES YAYINCILIK, IBRAHIM KARA, KIZILELMA CAD 5-3, FINDIKZADE, ISTANBUL 34096, TURKEY

Categories / Classification

Research Areas:General & Internal Medicine

Web of Science Categories:Medicine, General & Internal

Document Information

Document Type:Review

Language:English

Accession Number:WOS:000315504700002

PubMed ID:25206979

ISSN:2146-3123

Journal Information

 

Other Information

IDS Number:097WR

Cited References in Web of Science Core Collection: 24

Times Cited in Web of Science Core Collection: 1